
Opinion|Videos|April 10, 2025
Effect of High-Impact Site Involvement on Quality of Life
Panelists discuss how treating psoriasis in anatomically challenging areas such as the scalp, face, genitals, intertriginous zones, palms, soles, and nails requires specialized approaches due to unique barriers including limited penetration of topicals, skin sensitivity, mechanical friction, and psychological impact, necessitating tailored treatment strategies that may include modified vehicle formulations, careful steroid use, targeted phototherapy, or earlier consideration of systemic agents including biologics for these high-impact sites even when overall body surface involvement is limited.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some areas of the body that are particularly challenging to treat in psoriasis? What is your approach to treatment for these areas?
Advertisement
Related to this article

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.

Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.

In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.

Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Advertisement
Advertisement
Trending on HCPLive
1
Zabopegdutide Improves Fibrosis, MASH Resolution at 48 Weeks
2
Asundexian Receives FDA Approval for Secondary Stroke Prevention
3
RNA Editing With WVE-006 Restores Functional AAT, Cuts Z-AAT in AATD
4
Efinopegdutide Improves MASH Resolution, Fibrosis in Phase 2b Trial
5

